Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

merck sharp & dohme, lda. - vacina viva contra a varicela - pó e veículo para suspensão injetável - 1350 ufp/0.5 ml - vírus da varicela-zoster vivo 1350 u - varicella, live attenuated - vacina - duração do tratamento: curta ou média duração

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

merck sharp & dohme, lda. - vacina viva contra a varicela - pó e veículo para suspensão injetável - 1350 ufp/0.5 ml - vírus da varicela-zoster vivo 1350 u - varicella, live attenuated - vacina - duração do tratamento: curta ou média duração

Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

protim solignum ltd t/a koppers performance chemicals, c/o grant thornton, 13-18 city quay, dublin 2, d02 ed70 (airija). - vario(ii) karbonatas – vario(ii) hidroksidas (1:1); vario(ii) karbonatas – vario(ii) hidroksidas (1:1); vario(ii) karbonatas – vario(ii) hidroksidas (1:1); vario(ii) karbonatas – vario(ii) hidroksidas (1:1) - veikliosios medžiagos cas nr.: 12069-69-1, eb nr.: 235-113-6, veikliosios medžiagos pavadinimas: vario(ii) karbonatas – vario(ii) hidroksidas (1:1), koncentracija: 17.27% , veiklioji; veikliosios medžiagos cas nr.: 12069-69-1, eb nr.: 235-113-6, veikliosios medžiagos pavadinimas: vario(ii) karbonatas – vario(ii) hidroksidas (1:1), koncentracija: 17.27% , veiklioji; veikliosios medžiagos cas nr.: 12069-69-1, eb nr.: 235-113-6, veikliosios medžiagos pavadinimas: vario(ii) karbonatas – vario(ii) hidroksidas (1:1), koncentracija: 17.27% , veiklioji; veikliosios medžiagos cas nr.: 12069-69-1, eb nr.: 235-113-6, veikliosios medžiagos pavadinimas: vario(ii) karbonatas – vario(ii) hidroksidas (1:1), koncentracija: 17.27% , veiklioji - medienos konservantai

Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

bochemie a.s., lidicka 326, 735 95 bohumin (Čekija). - vario(ii) karbonatas – vario(ii) hidroksidas (1:1); vario(ii) karbonatas – vario(ii) hidroksidas (1:1); vario(ii) karbonatas – vario(ii) hidroksidas (1:1); vario(ii) karbonatas – vario(ii) hidroksidas (1:1) - veikliosios medžiagos cas nr.: 12069-69-1, eb nr.: 235-113-6, veikliosios medžiagos pavadinimas: vario(ii) karbonatas – vario(ii) hidroksidas (1:1), koncentracija: 15% , veiklioji; veikliosios medžiagos cas nr.: 12069-69-1, eb nr.: 235-113-6, veikliosios medžiagos pavadinimas: vario(ii) karbonatas – vario(ii) hidroksidas (1:1), koncentracija: 15% , veiklioji; veikliosios medžiagos cas nr.: 12069-69-1, eb nr.: 235-113-6, veikliosios medžiagos pavadinimas: vario(ii) karbonatas – vario(ii) hidroksidas (1:1), koncentracija: 15% , veiklioji; veikliosios medžiagos cas nr.: 12069-69-1, eb nr.: 235-113-6, veikliosios medžiagos pavadinimas: vario(ii) karbonatas – vario(ii) hidroksidas (1:1), koncentracija: 15% , veiklioji - medienos konservantai

Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

chugoku paints bv, sluisweg 12, nl-4794 sw heijningen, nyderlandai. - vario piritionas; vario piritionas; vario piritionas - veikliosios medžiagos cas nr.: 14915-37-8, eb nr.: 238-984-0, veikliosios medžiagos pavadinimas: vario piritionas, koncentracija: 5% , veiklioji; veikliosios medžiagos cas nr.: 14915-37-8, eb nr.: 238-984-0, veikliosios medžiagos pavadinimas: vario piritionas, koncentracija: 5% , veiklioji; veikliosios medžiagos cas nr.: 14915-37-8, eb nr.: 238-984-0, veikliosios medžiagos pavadinimas: vario piritionas, koncentracija: 5% , veiklioji

USA - engelsk - NLM (National Library of Medicine)

biocompatibles, inc. - polidocanol (unii: 0awh8bfg9a) (polidocanol - unii:0awh8bfg9a) - polidocanol 180 mg in 1 ml - varithena (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (gsv) system above and below the knee. varithena improves the symptoms of superficial venous incompetence and the appearance of visible varicosities. the use of varithena is contraindicated in patients with: - known allergy to polidocanol [see warnings and precautions (5.1)] - acute thromboembolic disease risk summary few published case reports with use of polidocanol-containing products, including varithena, in pregnant women have not identified any drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. although no risks have been identified, there is minimal benefit in treating lower extremity varicosities during pregnancy and lower extremity varicosities that develop during pregnancy as they may spontaneously regress postpartum. in animal reproduction studies, no adverse develo

Belgia - tysk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

msd belgium - varizellen-virus - pulver und lösungsmittel zur herstellung einer injektionssuspension - varizellen-virus - varicella, live attenuated

Malta - engelsk - Medicines Authority

glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - varicella virus, oka strain, live, attenuated, measles virus, schwarz strain, mumps virus, jeryl lynn, level b, rubella virus, wistar ra - powder and solvent for solution for injection - mumps virus jeryl lynn (level b) strain (live, attenuated) rubella virus - wistar ra27/3 strain varicella virus oka strain (live, attenuated) measles virus - schwarz strain - vaccines

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 2700 pfu/ml - injection, powder for - excipient ingredients: monosodium glutamate monohydrate; urea; sodium chloride; potassium chloride; sucrose; hydrolysed gelatin; monobasic potassium phosphate; dibasic sodium phosphate - varivax refrigerated is indicated for vaccination against varicella in healthy individuals 12 months of age and older.,see the australian immunisation handbook for vaccination recommendations and schedule.,groups who would particularly benefit from vaccination include:,? non-immune adults, especially those in at-risk occupations such as health-care workers, teachers and workers in children?s day-care centres.,? non-immune parents of young children.,? non-immune household contacts, both adults and children, of immunocompromised patients with no history of disease.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 2700 pfu/ml - diluent, not applicable - excipient ingredients: water for injections - varivax refrigerated is indicated for vaccination against varicella in healthy individuals 12 months of age and older.,see the australian immunisation handbook for vaccination recommendations and schedule.,groups who would particularly benefit from vaccination include:,? non-immune adults, especially those in at-risk occupations such as health-care workers, teachers and workers in children?s day-care centres.,? non-immune parents of young children.,? non-immune household contacts, both adults and children, of immunocompromised patients with no history of disease.